益髓生血颗粒治疗中间型α-地中海贫血及β-地中海贫血的临床观察

Clinical Observation of Yisui Shengxue Granule(益髓生血颗粒)in Treating α-thalassemia and β-thalassemia Intermedia

目的:探讨益髓生血颗粒治疗中间型α-地中海贫血及β-地中海贫血的疗效。方法:纳入中间型地中海贫血患者68例(α-地中海贫血42例、β-地中海贫血26例),采用益髓生血颗粒治疗,观察患者治疗前后血液指标(Hb、RBC、Ret)、中医证候积分及疗效。结果:α-地中海贫血患者治疗后Hb、RBC明显升高(P<0.01),中医证候积分明显降低(P<0.01),西医有效率为81.0%,中医有效率为67.6%;β-地中海贫血患者治疗后Hb、Ret明显升高(P<0.05),西医有效率为61.5%,中医有效率为31.6%。两组患者治疗后Hb升高幅度、中医证候积分、西医疗效比较,差异均无统计学意义(P>0.05);α-地中海贫血患者治疗后中医证候积分低于β-地中海贫血患者,中医证候疗效优于β-地中海贫血患者,差异均有统计学意义(P<0.05)。结论:益髓生血颗粒治疗中间型α-地中海贫血及β-地中海贫血在西医疗效方面无明显差别,但在中医疗效方面则存在明显的差异;益髓生血颗粒能有效提升中间型α-地中海贫血及β-地中海贫血的Hb水平,同时还能提升α-地中海贫血的RBC水平及β-地中海贫血的Ret水平,改善α-地中海贫血的中医证候,说明益髓生血颗粒在改善中间型α-地中海贫血及β-地中海贫血的血常规及中医证候方面存在不同的疗效特点。

Objective： To investigate the effects of Yisui Shengxue Granule （YSSXG） in the treatment of α- and β-thalassemia intermedia, make clear of the differenees of curative effect. Methods： A total of 68 cases of thalassemia intermedia（42 eases of α-thalassemia, 26 cases of β-thalassemia） were observed by the blood index, TCM syndrome score before and after the treatment of YSSXG, analyzed the curative effect of Chinese and Western medicine and its difference between the two types of thalassemia. Results： After YSSXG treatment, Hb and RBC of α-thalassemia increased signifieantly （P〈0.01）, TCM syndrome score deereased significantly（P〈0.01）, western medicine efficiency was 81% （34/42）, Chinese medieine efficieney was 71.9% （23/32）. Hb and Ret of β- thalassemia increased significantly （P〈0.05）, TCM syndrome score did not significantly decrease （P〉0.05）, western medicine efficiency was 61.5% （16/26）, Chinese medicine efficiency was 37.5% （6/16）. The two groups had no significant difference in increasing Hb levels at the end of the treatment, in TCM syndrome score before and af- ter treatment, and in western medicine efficiency （P〉0.05）. But at the aspect of improving TCM syndrome and the TCM therapeutic effect, α-thalassemia are better than β-thalassemia （P〈0.05）. Conclusion： There is no significant difference in the efficacy of western medicine in α-and β-thalassemia treating, but there is a significant differ- ence in the efficacy of Chinese medicine. YSSXG not only can effectively improve the Hb level of intermediate α-and β-thalassemia, but also can enhance the RBC level of α-thalassemia and Ret level of β-thalassemia, and significantly improve the TCM syndrome of α-thalassemia, indicating that YSSXG have different efficacy characteristics in the improvement of intermediate α-and β-thalassemia blood index and TCM syndrome.